Back to Search
Start Over
Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring.
- Source :
-
Ocular Immunology & Inflammation . Sep2024, Vol. 32 Issue 7, p1268-1273. 6p. - Publication Year :
- 2024
-
Abstract
- Purpose: We report the long-term effect of rituximab (RTX) in scleritis and determine the value of B-cell monitoring for the prediction of relapses. Methods: We retrospectively studied 10 patients with scleritis, who were treated with RTX. Clinical characteristics were collected, and blood B-cell counts were measured before the start of RTX, and at various time points after treatment. Results: Clinical activity of scleritis decreased after RTX treatment in all patients within a median time of 8 weeks (range 3–13), and all reached remission. The median follow-up was 101 months (range 9–138). Relapses occurred in 6 out of 10 patients. All relapses, where B-cell counts were measured (11 out of 19), were heralded by returning B cells. However, B cells also returned in patients with long-term remissions. Conclusions: RTX is a promising therapeutic option for scleritis. Recurrence of B cells after initial depletion does not always predict relapse of scleritis. [ABSTRACT FROM AUTHOR]
- Subjects :
- *B cells
*SCLERITIS
*RITUXIMAB
*REFRACTORY materials
Subjects
Details
- Language :
- English
- ISSN :
- 09273948
- Volume :
- 32
- Issue :
- 7
- Database :
- Academic Search Index
- Journal :
- Ocular Immunology & Inflammation
- Publication Type :
- Academic Journal
- Accession number :
- 179273411
- Full Text :
- https://doi.org/10.1080/09273948.2023.2229900